Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG384

—

6b265d90-82e8-5c14-b8f1-82f3cd17dcae

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PEROXISOME+0.434
  • ESTROGEN_RESPONSE_EARLY+0.359
  • MYOGENESIS+0.356
  • CHOLESTEROL_HOMEOSTASIS+0.290
  • APICAL_SURFACE+0.264
  • BILE_ACID_METABOLISM+0.256
  • XENOBIOTIC_METABOLISM+0.256
  • ESTROGEN_RESPONSE_LATE+0.249
  • APICAL_JUNCTION+0.247
  • SPERMATOGENESIS+0.240

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.352
  • IL6_JAK_STAT3_SIGNALING-0.332
  • INTERFERON_GAMMA_RESPONSE-0.295
  • INFLAMMATORY_RESPONSE-0.268
  • ALLOGRAFT_REJECTION-0.266
  • E2F_TARGETS-0.260
  • MYC_TARGETS_V2-0.244
  • G2M_CHECKPOINT-0.240
  • MYC_TARGETS_V1-0.198
  • KRAS_SIGNALING_UP-0.135

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG1099
mng-umap@100
——0.811
2MNG397
mng-umap@100
——0.799
3SRR8613741
breast-umap@18
—F0.792
4bd926132-883f-4056-b4a5-7dc0f54f3618
melanoma-umap@29
——0.774
5MNG965
mng-umap@100
——0.738
6TCGA-CV-6935-01A-11R-1915-07
head-neck@1
——0.733
7SRR8518241
breast-umap@18
—F0.733
8GSM6454744
breast-umap@18
—A0.724
9MNG529
mng-umap@100
——0.720
10SRR8613710
breast-umap@18
—F0.717

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PEROXISOME0.434Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.359Inavolisib— uncovered
MYOGENESIS0.356Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.290Remibrutinib— uncovered
APICAL_SURFACE0.264Temsirolimus— uncovered
BILE_ACID_METABOLISM0.256Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.256Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.249Idelalisib— uncovered
APICAL_JUNCTION0.247Inavolisib— uncovered
SPERMATOGENESIS0.240Inavolisib— uncovered
HYPOXIA0.229Idelalisib— uncovered
FATTY_ACID_METABOLISM0.227Inavolisib— uncovered
HEDGEHOG_SIGNALING0.221Inavolisib— uncovered
KRAS_SIGNALING_DN0.199Remibrutinib— uncovered
GLYCOLYSIS0.195Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.194Remibrutinib— uncovered
HEME_METABOLISM0.185Temsirolimus— uncovered
ANDROGEN_RESPONSE0.184Inavolisib— uncovered
UV_RESPONSE_UP0.167Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.147Inavolisib— uncovered